Stockwinners Market Radar for October 28, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:22 EDT Lockheed Martin awarded $111.12M Navy contract modification - Lockheed Martin was awarded a $111.12M cost-plus-fixed-fee, cost-plus-incentive-fee modification to a previously awarded contract. This modification adds scope for the development of a Common Reprogramming Tool, or CRT, minimum viable product, as well as establishing network connections required to establish the CRT development network and selection of a service-oriented architecture needed to commence development of enhanced reprogramming tools in support of efforts to replace legacy programming tools utilized by reprogramming labs to modernize and revolutionize F-35 reprogramming. Work was expected to be completed in October 2024. FY22 research, development, test and evaluation funds in the amount of $4.73M; FY22 research, development, test and evaluation funds in the amount of $3.66M and non-U.S. Department of Defense partner funds in the amount of $1.6M will be obligated at the time of award, $8.39M of which will expire at the end of the current fiscal year. The Naval Air Systems is the contracting activity.

17:15 EDT Mogo receives Nasdaq notification regarding minimum bid price deficiency - Mogo announced that on October 28, 2022, it received a written notification from the Nasdaq Stock Market LLC indicating that, for the last thirty consecutive business days, the bid price for the company's common shares had closed below the minimum $1.00 per share requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(a)(2). The Notification Letter is only a notification of deficiency and has no immediate effect on the listing or trading of the Shares and the Shares will continue to trade on Nasdaq under the symbol "MOGO." The Shares are also listed on the Toronto Stock Exchange and the Notification Letter does not affect the company's compliance status with such listing.

16:39 EDT PepsiCo senior VP Gallagher sells 5,558 common shares - In a regulatory filing, PepsiCo senior VP and controller Marie Gallagher disclosed the sale of 5,558 common shares of the company on October 26 at a price $180.0082 per share.

16:18 EDT Y-mAbs Therapeutics falls 43% to $5.06 after FDA panel vote on omburtamab

16:10 EDT Akso Health receives Nasdaq notification regarding minimum bid price deficiency - Akso Health Group announced that the company has received a written notification from the Nasdaq Stock Market LLC on October 26, 2022, notifying the company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the company's ADSs for the 30 consecutive business days from September 12, 2022 to October 25, 2022, the company no longer meets the minimum bid price requirement.

16:06 EDT Taitron raises quarterly dividend 11.1% to 5c from 4.5c per share - Payable on November 30 to stockholders of record as of the close of business on November 11.

15:51 EDT User reports indicate problems at Meta's Facebook, Downdetector says - Reference Link

15:37 EDT Y-mAbs 'disappointed' by 16 to 0 vote against omburtamab by FDA advisors - Y-mAbs Therapeutics announced the outcome of the meeting of the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee, or "ODAC," which reviewed investigational 131I-omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma. The committee voted 16 to 0 that the company had not provided sufficient evidence to conclude that omburtamab improves overall survival. ODAC reviewed data from omburtamab's clinical development program with a focus on study 03-133, a pivotal phase 1 study, and study 101, a pivotal phase 2 study, as well as the historical control group. "We are disappointed by the outcome of today's meeting, as patients with CNS/leptomeningeal metastasis from neuroblastoma are in need of effective and safe treatment options. Y-mAbs is committed to working closely with the FDA on their review of the Biologic License Application for omburtamab ahead of their decision. We want to thank all of the patients, caregivers, and healthcare providers who participated in the studies of this life-threatening condition," said Thomas Gad, President, and Interim CEO. Y-mAbs BLA submission for omburtamab was accepted for Priority Review by the FDA on May 31, 2022, with a Prescription Drug User Fee Act, or "PDUFA," target date of November 30. "The FDA is not bound by the Advisory Committee's recommendations but generally takes the recommendation into consideration when making its decision. Researchers at MSK developed omburtamab, which is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the compound," the company noted.

14:37 EDT BankFinancial extends and expands share repurchase program - The board of directors of BankFinancial extended the expiration date of the company's share repurchase authorization from February 28, 2023 to April 28, 2023, and increased the total number of shares currently authorized for repurchase under the share repurchase program to 318,689 shares. As of October 27, a total of 18,689 shares remained authorized for purchase pursuant to the previous share repurchase authorization. Therefore, as of October 27, the total number of shares authorized for repurchase increased 300,000 shares to 318,689 shares.

14:15 EDT Zions Bancorp approves Q4 share repurchase for up to $50M - Zions Bancorporation announced that its board authorized a share repurchase for Q4 of up to $50M. The board also declared a regular quarterly dividend of 41c per common share, payable November 17, to shareholders of record at the close of business on November 10.

13:31 EDT NYSE tells SEC will remove Twitter from exchange on November 8 - In a regulatory filing, the New York Stock Exchange disclosed that it has notified the SEC of its intention to remove the entire class of Twitter securities from listing and registration on the Exchange at the opening of business on November 8. "The merger between Twitter, Inc. and X Holdings II, Inc., a wholly owned subsidiary of X Holdings I, Inc., wholly owned by Elon R. Musk became effective on October 27, 2022. Each share of Twitter, Inc. Common Stock was exchanged for USD 54.20 in cash, without interest and less any applicable withholding taxes. The Exchange also notifies the Securities and Exchange Commission that as a result of the above indicated conditions this security was suspended from trading before market open on October 28," the filing [stated.]:[https://www.sec.gov/Archives/edgar/data/876661/000087666122000890/0000876661-22-000890.txt]

13:03 EDT Baker Hughes reports U.S. rig count down 3 to 768 rigs - Baker Hughes reports that the U.S. rig count is down 3 from last week to 768 with oil rigs down 2 to 610, gas rigs down 1 to 156 and miscellaneous rigs unchanged at 2. The U.S. Rig Count is up 224 rigs from last year's count of 544 with oil rigs up 166, gas rigs up 56 and miscellaneous up 2. The U.S. Offshore Rig Count is down 1 to 14, up 1 year-over-year. The Canada Rig Count is up 2 from last week to 212, with oil rigs up 1 to 145, gas rigs up 1 to 67. The Canada Rig Count is up 46 rigs from last year's count of 166, with oil rigs up 47, gas rigs down 1.

12:09 EDT TD Bank establishes Wealth Management, Insurance reporting segment - TD Bank Group announced a new alignment of its reportable business segments to establish a Wealth Management and Insurance segment. This change is effective the beginning of the fourth quarter of 2022 and reflects how the Bank will now view its businesses for management reporting purposes. Previously, Wealth Management and Insurance was reported along with Canadian Personal and Commercial Banking in the Canadian Retail segment. The Bank will report its results under the following segments, with comparative periods showing the new aligned segments: Canadian Personal and Commercial Banking, comprised of the Canadian personal and commercial banking businesses which provides financial products and services to personal, small business and commercial customers, and TD Auto Finance Canada. U.S. Retail, comprised of the personal and business banking businesses in the U.S. operating under the brand TD Bank, primarily in the Northeast and Mid-Atlantic regions and Florida, TD Auto Finance U.S., and the U.S. wealth business, including Epoch and the Bank's equity investment in Schwab. Wealth Management and Insurance, includes the Canadian wealth business which provides investment products and services to institutional and retail investors, and the insurance business which provides property and casualty insurance, as well as life and health insurance products to customers across Canada.Wholesale Banking, provides a wide range of capital markets, investment banking, and corporate banking products and services, including underwriting and distribution of new debt and equity issues, providing advice on strategic acquisitions and divestitures, and meeting the daily trading, funding, and investment needs of the Bank's clients. Corporate, includes the Bank's other activities.

12:00 EDT Edwards Lifesciences falls -16.6% - Edwards Lifesciences is down -16.6%, or -$14.31 to $71.99.

12:00 EDT Flagstar Bancorp rises 13.7% - Flagstar Bancorp is up 13.7%, or $4.65 to $38.48.

12:00 EDT 8x8 rises 14.1% - 8x8 is up 14.1%, or 48c to $3.89.

11:10 EDT Venus Acquisition Corp trading halted, volatility trading pause

10:31 EDT Bull Horn Holdings Corp trading resumes

10:23 EDT New Fortress Energy finalizes agreement with Comision Federal de Electricidad - New Fortress Energy announced that it has finalized its agreements with Comision Federal de Electricidad as part of a growing strategic alliance supported by His Excellency Andres Manuel Lopez Obrador, the President of Mexico, and by Manuel Bartlett, the CEO of CFE. The final agreements, which were originally announced on July 5 and are expected to be executed at a ceremony planned for November 3 in Mexico City, involve expanding and extending NFE's supply of natural gas to multiple CFE power generation facilities in Baja California Sur, selling NFE's 135 MW La Paz power plant to CFE, and creating a new FLNG hub off the coast of Altamira, Tamaulipas, with CFE supplying requisite feedgas to multiple NFE FLNG units using CFE's existing and underutilized pipeline capacity. In July 2021, NFE commenced commercial operations of an LNG regasification terminal in the port of Pichilingue, La Paz, Baja California Sur. The terminal, which features NFE's proprietary ISOFlex system, is optimally positioned to supply natural gas to CFE's generation facilities in the otherwise resource-stranded region, which include CTG La Paz and CTG Baja California Sur. As part of the agreements, CFE and NFE will extend the term and increase the volume of NFE's gas supply agreement to CFE's power generation facilities in the region. Additionally, NFE will sell its own 135 MW Central Turbogas Amaunet power plant in La Paz to CFE, further enhancing NFE's ability to internally fund strategic growth initiatives that service our customers' needs amid a structurally short global LNG market. The addition of this power plant to CFE's generation fleet is expected to enhance system reliability, reduce power costs, and complement steps CFE is taking to expand the use of renewable energy resources and lower emissions in the region by nearly half a million tons of CO2 per year. NFE and CFE are collaborating on the creation of a new FLNG hub off the coast of Altamira, Tamaulipas. Pursuant to the now finalized agreements, NFE will deploy multiple FLNG units of 1.4 MTPA each that utilize CFE's existing firm pipeline transportation capacity on TC Energy's Sur de Texas-Tuxpan Pipeline to deliver feedgas volumes to NFE. NFE's first FLNG unit, which is under construction at the Kiewit Offshore Services shipyard near Corpus Christi, Texas, is currently expected to achieve mechanical completion in March 2023, and will be delivered to Altamira for commencement of operations soon thereafter. As part of the agreements, CFE would share in the production and marketing of a portion of the LNG volumes from the new Altamira offshore FLNG hub

10:00 EDT Edwards Lifesciences falls -14.3% - Edwards Lifesciences is down -14.3%, or -$12.32 to $73.98.

10:00 EDT World Fuel Services falls -16.5% - World Fuel Services is down -16.5%, or -$4.47 to $22.71.

10:00 EDT PennyMac Financial rises 14.7% - PennyMac Financial is up 14.7%, or $6.93 to $54.15.

10:00 EDT 8x8 rises 17.2% - 8x8 is up 17.2%, or 59c to $4.00.

09:55 EDT Y mAbs Therapeutics trading halted, news pending

09:47 EDT KE Holdings falls -16.1% - KE Holdings is down -16.1%, or -$1.79 to $9.32.

09:47 EDT DaVita falls -19.9% - DaVita is down -19.9%, or -$19.25 to $77.50.

09:47 EDT Pinterest rises 14.4% - Pinterest is up 14.4%, or $3.15 to $25.04.

09:44 EDT LMF Acquisition Opportunities Inc trading halted, volatility trading pause

09:42 EDT Carlisle trading resumes

09:36 EDT Omega Therapeutics trading halted, volatility trading pause

09:35 EDT Carlisle trading halted, volatility trading pause

09:31 EDT SLNA Stock trading halted, volatility trading pause

09:21 EDT Terreno Realty executes early lease in Rancho Dominguez - Terreno Realty announced that it has executed an early lease renewal for 66,000 square feet in Rancho Dominguez, California with a provider of third-party logistics in the Southwestern U.S. and Mexico. The lease, which was to expire in April 2023, will now expire May 2026.

09:08 EDT AbbVie says seeing slowdown in aesthetic procedures due to inflation - Expects this slowdown to persist into 2023 until consumer confidence improves. Sees "strong access" to Humira in 2023. Comments taken from Q3 earnings conference call.

09:04 EDT First Citizens appoints Eugene Flood to board of directors - Eugene Flood Jr. has been appointed to the Board of Directors of First Citizens BancShares and its First-Citizens Bank & Trust Company subsidiary, effective Jan. 1, 2023. He fills the vacancy that will be created by the retirement of director Daniel Heavner, effective Dec. 31, 2022. Heavner has served as a director since 2007. Flood is a former president and chief executive officer of Smith Breeden Associates.

09:02 EDT TrueCar sees October total new vehicle industry sales 1,165,658 units, up 15% - TrueCar expects total new vehicle industry sales to reach 1,165,658 units in October 2022, up 15% from a year ago and about on par with September 2022, when adjusted for the same number of selling days. This month's seasonally adjusted annualized rate for total light vehicle industry sales is an estimated 14.6M, up 13% from October 2021. Excluding fleet sales, TrueCar expects U.S. retail deliveries of new cars and light trucks to be 995,808 units, up 9% from a year ago and down about 2% from September 2022.

09:01 EDT Micron Foundation, NSF, Schumer commit $10M for semiconductor education - Micron Technology and the Micron Foundation, along with U.S. Senate Majority Leader Charles E. Schumer announced a new partnership with the U.S. National Science Foundation, committing to a joint investment of $10 million to fund and develop semiconductor curricula in colleges and universities across the country. NSF will match the Micron Foundation's initial donation of $5 million over the next five years, enabling the development of high-quality educational material, offering educators options for professional development and providing students with experiential opportunities in the semiconductor industry. Micron and NSF will work together to direct the funds towards these programs and towards innovative academic research in the high technology memory field.

08:52 EDT Genmab submits subcutaneous epcoritamab BLA to FDA - Genmab (GMAB) announced that the company has submitted a Biologics License Application to the FDA for subcutaneous epcoritamab, an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma, or LBCL, after two or more lines of systemic therapy. Additionally, Genmab announced that AbbVie (ABBV) submitted a Marketing Authorization Application, or MAA, for epcoritamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy, which has been validated by the European Medicines Agency.

08:45 EDT Nuvalent reports preliminary Phase 1 clinical data from ARROS-1 trial - Nuvalent announced the initial data from the Phase 1 dose-escalation portion of its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer, NSCLC, and other solid tumors. As of the preliminary data cut-off date of September 13, 2022, no dose-limiting toxicities, treatment-related serious adverse events, treatment-emergent dizziness, or adverse events leading to treatment reductions or discontinuations were observed. Preliminary activity data reported as of the data cut-off date were available from 21 heavily pre-treated response-evaluable NSCLC patients, of which partial responses were observed in 48%. To evaluate key target characteristics of NVL-520, activity was examined in subgroups including: Patients with ROS1 G2032R mutations - Objective Response Rate, ORR, 78%, 7/9; Patients with a history of CNS metastases - ORR 73%, 8/11; The most heavily pre-treated of patients, receiving two or more prior ROS1 TKIs and one or more prior lines of chemotherapy - ORR 53%, 9/17; and Patients previously treated with lorlatinib or repotrectinib - ORR 50%, 9/18. As of the preliminary data cut-off date, 76% of response-evaluable patients continued on NVL-520 treatment. Enrollment in the Phase 1 portion of the trial is ongoing. "We believe today's preliminary results further support Nuvalent's approach of applying innovative chemistry and structure-based drug design to well-defined target product profiles focused on addressing medical needs that have been identified in collaboration with leading physician-scientists," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "Not only has this approach rapidly delivered the encouraging preliminary results for NVL-520 presented today, it underpins our work across our entire pipeline, including parallel lead candidate NVL-655 for ALK-positive NSCLC, and our recently announced development candidate for HER2ex20-driven cancers, NVL-330"

08:35 EDT Benessere Capital Acquisition provides update on intended liquidation - Benessere Capital Acquisition announced that, further to the prior announcement of its determination to liquidate, the effective date for the Company's redemption of all of its outstanding shares of Class A common stock, will be October 31, 2022. Net of taxes and dissolution expenses, the per-share redemption price for the public shares is expected to be approximately $10.45. The Company anticipates that the Class A Shares will cease trading as of the close of business on October 31, 2022. As of November 1, 2022, the Class A Shares will be deemed cancelled and will represent only the right to receive the Redemption Amount. The Redemption Amount will be payable to the holders of the Class A Shares upon presentation of their respective share or unit certificates or other delivery of their shares or units to the Company's transfer agent, Continental Stock Transfer & Trust Company. Beneficial owners of Class A Shares held in "street name," however, will not need to take any action in order to receive the Redemption Amount. There will be no redemption rights or liquidating distributions with respect to the Company's warrants and rights, which will also cease trading as of the close of business on October 31, 2022. The Company's initial stockholders have waived their redemption rights with respect to the outstanding shares of Class B common stock issued prior to the Company's initial public offering. The Company expects that Nasdaq will file a Form 25 with the U.S. Securities and Exchange Commission to delist its securities.

08:25 EDT Greenlane announces $7.5M public offering - Greenlane Holdings announced the pricing of its "reasonable best efforts" public offering of 8,333,335 units at a public offering price of $0.90 per unit. Each unit consists of one share of Class A common stock and two common warrants each exercisable for one share of Class A common stock at an exercise price of $0.90 per share. The common warrants will be immediately exercisable and expire seven years from the date of issuance. The pre-funded warrants and accompanying common warrants are identical to the units, except that each pre-funded warrant is immediately exercisable for one share of Class A common stock at an exercise price of $0.0001, the purchase price for a pre-funded warrant and accompanying common warrants is $0.8999 and the pre-funded warrants do not expire until exercised. Gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $7.5M. The closing of the offering is expected to occur on or about November 1, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for general corporate purposes,which may include, without limitation, servicing debt obligations under promissory notes issued in conjunction with business acquisitions, working capital, product development and capital expenditures.

08:17 EDT Zentek provides update on battery technology development - Zentek announces the commencement of a 4-year, $1.6M research project in collaboration with Professors Mohini Sain and Ning Yan from the University of Toronto and Ford Powertrain Engineering Research and Development Centre. Funding for the project includes $1.2M from the Mitacs Accelerate program. Prof. Sain is the Endowed Ford Motor Canada Chair in Sustainable Materials where he is active in the field of light energy storage including cell chemistry and renewable fuel battery development at PERDC, and Prof. Yan is the Tier 1 Canada Research Chair in Sustainable Bioproducts. Collaborating with the PERDC and testing at this facility is essential to demonstrate battery advances at a scale suitable for the automotive industry. The project seeks to test novel concepts for the purpose of inventing multifunctional materials to be used in automotive battery components including anode, cathode, electrolyte, and separator. Zentek will be working in tandem with U of T researchers providing and testing advanced graphene materials including Zentek's patent-pending anode material developed by Dr. Michael Pope. Further to Zentek's press releases dated November 22, 2018 and February 18, 2022, Zentek has been collaborating with Dr. Michael Pope at the University of Waterloo for the last three years, developing battery technology to improve anode performance. One highly studied area for lithium-ion battery development is to improve the anode material. Currently electric vehicle anodes are composed of graphite, which has a limited theoretical specific capacity of ~372 mAhg-1. Silicon has attracted significant attention as a replacement material, mainly due to its high specific capacity of 4,200 mAhg-1, but also due to its low working potential, low price and the availability of silicon. However, the industrialization of silicon anodes is hindered by an important engineering roadblock: silicon has an enormous volumetric fluctuation when charging and discharging. This feature is the root cause behind three major issues: Poor cycle lifetime due to self-pulverization of the anode. Irreversible capacity loss and low coulombic efficiency. Destruction and reformation of the solid-electrolyte interface, which consumes electrolyte and causes thickening and poor ionic mobility. Using silicon in the anode material, Dr. Pope has addressed these issues, and has created a patent-pending graphene wrapped silicon anode material. Key characteristics of graphene-wrapped silicon anode, as announced in February 2022 include: At practical mass loading of 2.5mg/cm2, the electrode achieved 2.04 mAh/cm2 and retained 79% of this capacity after 200 cycles against a lithium half-cell. When paired with a commercial lithium iron phosphate cathode, the fully assembled battery retained 93.3% of its initial capacity over 100 cycles. Works with current lithium-ion batteries as a replacement for graphite. Since April, Dr. Pope's team has optimized the anode material, which now has a specific capacity of over 1,000 mAh/g and retains over 80% of its capacity over 320 charge-discharge cycles. The specific capacity of this material is a significant improvement over common graphite anodes; however, the cycle life still requires improvement compared to typical electric vehicle batteries, which lose about 4% capacity over 1,000 charge-discharge cycles. Zentek and Dr. Pope's team will continue to develop this technology with the goal of improving performance to meet industry requirements. Newly optimized chemistries are reaching specific capacities as high as 1,500 mAh/g, an over 400% improvement over graphite anodes. This significant improvement in energy density is complemented by impressive cycle stability. These performance tests were done under accelerated protocols and will need to be confirmed in standard tests.

08:16 EDT Weyerhaeuser announces resolution of work stoppage in Oregon, Washington - Weyerhaeuser announced the successful resolution of a work stoppage involving members of the International Association of Machinists and Aerospace Workers union in Oregon and Washington. Weyerhaeuser has approximately 1,200 employees who are members of IAM, including employees in the company's Wood Products and Timberlands organizations, and the approval of a new contract will result in the restoration of operations at all sites.

08:12 EDT Activision Blizzard announces release of Call of Duty: Modern Warfare II - Call of Duty: Modern Warfare II is now available for play. Call of Duty: Modern Warfare II includes a single-player campaign, multiplayer action, and a new Special Ops tactical cooperative experience for Call of Duty players. The company also announced that the new, free-to-play Warzone 2.0 is coming on November 16.

08:09 EDT AC Immune sees cash runway into 3Q24 - The Company had a total cash balance of CHF 140.5 million, composed of CHF 44.5 million in cash and cash equivalents and CHF 96.0 million in short-term financial assets. This compares to a total cash balance of CHF 198.2 million as of December 31, 2021. The Company's cash balance provides cash for operations into Q3 2024 without consideration of potential incoming milestone payments.

07:50 EDT GSK says EMA accepts MAA for RSV vaccine candidate - GSK announced that the European Medicines Agency has validated the marketing authorization application, or MAA, for its respiratory syncytial virus, or RSV, older adult vaccine candidate. "MAAs may be eligible for accelerated assessment if the EMA's Committee for Medicinal Products for Human Use decides the product is of major interest for public health and therapeutic innovation. A European regulatory decision is anticipated in Q3 2023. If approved, GSK's RSV older adult vaccine candidate has the potential to be the first vaccine available to help protect older adults from RSV lower respiratory tract disease," GSK stated.

07:49 EDT SciSparc says Wellution launches keto gummies apple cider vinegar product - SciSparc announced that SciSparc Nutraceuticals Inc., its wholly owned subsidiary, has successfully launched a new keto gummies apple cider vinegar product under its brand Wellution on Amazon.com. In the 30 days following the launch, the new product has generated more than $100,000 in revenues with an ROI to the Company of approximately 117%.

07:47 EDT AbbVie CEO says seeing 'strong momentum from our key immunology assets' - "We continue to see strong momentum from our key immunology assets, Skyrizi and Rinvoq, and this performance - combined with strength from other growth drivers within our diverse portfolio - has mitigated the impact of temporary economic headwinds on our aesthetics products to deliver another quarter of strong results," said Richard Gonzalez, chairman and CEO, AbbVie. "Based upon our performance and confidence in AbbVie's long-term outlook, we are once again meaningfully raising our dividend."

07:44 EDT Australis Capital provides corporate update for investors - Australis Capital is pleased to provide the following corporate update: New Jersey - AUDACIOUS Receives Notification From New Jersey On October 25, 2022, the State of New Jersey State issued AUDACIOUS its Conditional Class 1-Cultivator and Conditional Class 2-Manufacturer licenses. The Company can now submit conversion licenses applications to convert these conditional licenses to Annual Adult Usage Cultivation and Manufacturing licenses. Once received, the annual licenses allow AUDACIOUS to grow, manufacture, sell and distribute adult use cannabis in the State of New Jersey. It is expected that the state will soon open the application process to allow Class 1&2 holders to officially apply for Class 3&4 licenses. ALPS Subsidiary LarssenGC Continues to Win - Projects Secured in India and the U.S. LarssenGC, a wholly owned subsidiary of ALPS continues to win clients with its innovative approaches to cultivation with significant project wins in India and the U.S. The project in India, to be located in Pune near Mumbai, will be a 64-acre greenhouse for the cultivation of vegetables. LarssenGC also was engaged by a large U.S. based vegetable grower for end-to-end consulting and construction management services for a greenhouse complex of up to 70 acres. This is a significant project with up to $2 million in contract fees for LarssenGC. On the back of prior successful collaboration with a middle eastern partner on a major greenhouse project, the companies have now further cemented their relationship through the signing of a Master Services Agreement whereby LarssenGC becomes the partner of choice for all of this company's intended projects. New York The Company recently announced it had completed its first harvest in New York with its partner Hempire. The harvest has now been pre-processed. Our cannabis will now be further processed into vapes and edible products, to be sold to social equity dispensaries. As mentioned, the Company is in discussions with many of the applicants, with licenses anticipated to be granted shortly. LOOS - Continues to Sell Out The Company's shot brand, LOOS, continues to do well in California, driven by the quality of its offering, as well as the fact that the Company's products are available through EAZE, the world's largest legal cannabis delivery service. The most recent product batch has now sold out, with a new product run planned shortly. Additionally, the Company has engaged with a new distributor, YBL, who were behind the Kwikeaze shot brand achieving market leadership. Mr. Natural The Mr. Natural brand's most recent production run was the largest to date & is expected to be sold out shortly. Both the RSO and flower products have been in great demand with veterans and other medical cannabis consumers suffering from P.T.S. and similar conditions. The Company is sourcing new raw material suppliers to scale up sales of the Mr. Natural brand in order to meet continuously growing demand. Funding The Company announced a funding relationship with LDA in December 2021. While the Company has utilized some of the facility, it has switched gears to secure alternative sources of capital, including the recently announced credit facility provided by Terry Booth-owned Lola Ventures In addition, the Company is pleased to announce it has expanded its facility with Lola Ventures to provide funding of up to $4 million, the previous facility was $2.5 million. Cease Trade Order The Company is still under a Cease Trade Order. An update from our Audit team says the financial reporting required is progressing in a satisfactory manner. The company will keep shareholders informed with respect to its late filings.

07:34 EDT NextEra Energy Partners announces year-end 2023 run rate expectations - "NextEra Energy Partners delivered strong financial performance during the quarter, with third-quarter 2022 adjusted EBITDA and CAFD up approximately 13% and 17%, respectively, against the prior-year comparable quarter," said John Ketchum, chairman and CEO of NextEra Energy Partners. "During the third quarter, we completed the previously announced acquisition of an approximately 67% interest in a 230-megawatt, 4-hour battery storage facility in California from NextEraEnergy Resources. Consistent with our long-term growth prospects, today we are also introducing yearend 2023 run-rate expectations, reflecting roughly 23% and 12% growth, respectively, from our previously announced year-end 2022 run-rate adjusted EBITDA and cash available for distribution midpoints. We continue to believe 12% to 15% growth per year in limited partner distributions per unit is a reasonable range of expectations through at least 2025 and that NextEra Energy Partners offers a compelling investor value proposition."

07:22 EDT NeoGenomics provides update on MolDX submission for CRC - NeoGenomics is providing an update on its discussions with MolDX and on its commercial launch activities for RaDaR, its proprietary assay for the detection of minimal residual disease and recurrence.Late last week, MolDX informed the Company that additional clinical evidence is needed in order to secure Medicare coverage for RaDaR for Colorectal Cancer. Specifically, MolDX asked for a direct comparison with other MRD tests being utilized or a full clinical study. Therefore, due to the strength of published clinical data, the Company will prioritize commercial and reimbursement efforts in breast cancer, with an accelerated commercial launch of RaDaR for breast cancer targeted for Q1, 2023. Clinical data supporting the use of RaDaR in early stage breast cancer have been presented in both published papers and through presentations at professional meetings. In addition, NeoGenomics will launch RaDaR for CRC in the first quarter, while also expanding clinical research studies to support reimbursement from Medicare and other payors. Our precision medicine team is fully trained on RaDaR and excited to get this technology in the hands of oncologists and surgeons in the US for both breast cancer and CRC applications. Moreover, the Company continues to see strong demand from Pharmaceutical companies for RaDaR across all cancer types and will increase the RaDaR capacity in the US and UK to meet this need.

07:18 EDT Alliance Resource Partners increases cash distribution to 50c per unit - Alliance Resource Partners announced that the board of directors of ARLP's general partner approved an increased cash distribution to its unitholders for the quarter ended September 30. ARLP unitholders will receive a cash distribution for the 2022 quarter of 50c per unit, payable on November 14 to all unitholders of record as of the close of trading on November 7. The announced distribution represents a 150% increase over the cash distribution of 20c per unit for the quarter ended September 30, 2021 and a 25% increase over the cash distribution of 40c per unit for the quarter ended June 30, 2022.

07:13 EDT Hello Group CEO Li Wang resigns, Yan Tang to succeed - Hello Group announced that Li Wang has resigned as the CEO of the company, because of health reasons, effective immediately. Executive Chairman Yan Tang has assumed the role of CEO. Li Wang will remain with Hello Group as an executive director and president of the company, assisting Yan Tang in executing the company's core strategies.

07:10 EDT Medicenna Therapeutics receives Nasdaq deficiency notice - Medicenna Therapeutics announced that on October 25, 2022, it received a notice from the Nasdaq Stock Market, stating that the Company is not in compliance with the minimum bid price requirement of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the Company's common stock for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing or trading of the Company's common stock on Nasdaq, and the Company's operations are not affected by the receipt of the Notice. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days from the date of the Notice, or until April 24, 2023, to regain compliance with the Minimum Bid Requirement, during which time the Company's common stock will continue to trade on Nasdaq.

07:09 EDT Mereo BioPharma reaches cooperation agreement with Rubric Capital - Mereo BioPharma Group announced it has entered into a cooperation agreement with Rubric Capital Management, its largest shareholder. Pursuant to the Agreement, four new directors - Dr. Annalisa Jenkins, Dr. Daniel Shames, Mr. Marc Yoskowitz and Mr. Justin Roberts - will be appointed to the Company's Board of Directors as soon as practicable. Concurrent with these appointments taking effect, directors Dr. Peter Fellner, Dr. Brian Schwartz, Dr. Abdul Mullick and Ms. Anne Hyland will resign from the Board. Rubric has withdrawn its notice dated October 3, 2022 which required Mereo to call a General Meeting of its shareholders. In light of the Agreement with Rubric and the withdrawal of the Requisition Notice, the chair of the General Meeting, which is scheduled to be held on November 18, 2022, intends to present a motion withdrawing the Resolutions. It is not intended that the resolutions proposed by Rubric in the withdrawn Requisition Notice will be put to a vote. Shareholders are encouraged not to attend, submit voting instructions or proxies for, or take any other action in relation to the General Meeting.

07:08 EDT Himax announces divestiture of Emza Visual Sense subsidiary - Himax Technologies announced that it has divested its wholly owned subsidiary Emza Visual Sense, a company dedicated to the development of proprietary vision machine-learning algorithms. Following the transaction, Himax will continue to partner with Emza. The divestiture will not affect the existing business with the leading laptop customer where Himax continues to be the supplier for the leading-edge ultralow power AI processor and always-on CMOS image sensor. WiseEye, Himax's total solution for ultralow power AI image sensing, includes Himax proprietary AI processors, CMOS image sensors, and CNN-based machine-learning AI algorithms, all featuring unique characteristics of ultralow power consumption. Moving forward, the AI business model will be unchanged where the Company will continue to develop its own algorithms and work with third-party algorithms partners, including Emza.

07:07 EDT Colgate-Palmolive CEO says negative impact from currency accelerated in Q3 - Wallace, Chairman, President and CEO, commented on the Base Business third quarter results, "We are very pleased to have delivered our 15th consecutive quarter of organic sales growth at or above our targeted range of 3% to 5%. Net sales increased 1.0%, and organic sales grew 7.0% with growth in every division and in all four of our categories. The consistent, strong, broad-based growth is evidence that our strategies are working. Our focus on science-led, core and premium innovation is providing value at all price points, which is particularly important in today's difficult macroeconomic environment. Our investments in building and scaling our digital and other capabilities across the enterprise are also paying off with our revenue growth management initiatives helping to drive double-digit pricing worldwide. As expected, significant increases in raw and packaging material and logistics costs continued during the quarter and the negative impact from currency accelerated. Beyond revenue growth management and the significant pricing actions we are taking, we are also continuing our efforts around funding-the-growth and other productivity initiatives to help offset these headwinds. Looking ahead, despite the challenging macroeconomic environment, we intend to continue to execute against our strategy in order to drive value for all stakeholders."

07:06 EDT Synaptics acquires Emza Visual Sense, extends leadership position - Synaptics Incorporated announced the acquisition of Emza Visual Sense. The addition extends Synaptics' leadership position in Edge AI and allows it to immediately serve the PC market with a proven solution for human presence detection applications, supporting look-away detect and on-looker detect features. "We're very excited about integrating and scaling the Emza team's expertise and technology across our business," said Saleel Awsare, SVP & GM at Synaptics. "Bringing together key enabling technologies in edge hardware and algorithms for computer vision, audio, and security, while leveraging decades of experience and deep knowledge of customers' requirements, will allow us to together rapidly deploy, scale, and re-define the HPD experience."

07:05 EDT Garmin wins patent lawsuit vs. Logantree - Garmin subsidiary Garmin International announced victory in a patent lawsuit brought by Logantree against Garmin in Kansas federal court. After three days of testimony, the jury found that Garmin's popular smartwatches did not use any of Logantree's allegedly patented technology. The jury's verdict is subject to appeal.

07:03 EDT Charter reports Q3 total residential and SMB Internet customers up 75,000 - Third quarter total residential and small and medium business Internet customers increased by 75,000. As of September 30, 2022, Charter served a total of 30.3 million residential and SMB Internet customers. Third quarter total residential and SMB mobile lines increased by 396,000. As of September 30, 2022, Charter served a total of 4.7 million mobile lines. As of September 30, 2022, Charter had a total of 32.1 million residential and SMB customer relationships, which excludes mobile-only relationships.

06:49 EDT Booz Allen reports 9.8% increase in quarterly backlog to $31.8B - Quarterly Book-to-Bill of 2.40x.

06:46 EDT U.S. Silica sees FY22 capital expenditures $40M-$50M - The company said, "The Company remains focused on generating free cash flow and de-levering the balance sheet and intends on being operating cash flow positive in 2022, keeping an estimated $40-$50 million of capital expenditures within operating cash flow."

06:35 EDT Exxon Mobil raises quarterly dividend to 91c per share - "The Corporation declared a fourth-quarter dividend of 91c per share, payable on December 9th. The increase of 3c per share reflects confidence in our strategy, businesses performance, and financial strength, and marks 40 consecutive years of annual dividend growth."

06:34 EDT Exxon Mobil reports Q3 free cash flow $22B

06:18 EDT Chevron reports Q3 U.S. downstream earnings $1.29B - U.S. downstream operations reported earnings of $1.29 billion in third quarter 2022, compared with earnings of $1.08 billion a year earlier. The increase was mainly due to higher margins on refined product sales, partially offset by lower earnings from the 50 percent-owned Chevron Phillips Chemical Company and higher operating expenses that were largely associated with planned turnarounds. Refinery crude oil input in third quarter 2022 decreased 13 percent to 779,000 barrels per day from the year-ago period, primarily due to planned turnarounds. Refined product sales of 1.25 million barrels per day were up 5 percent from the year-ago period, mainly due to higher renewable fuel sales following the Renewable Energy Group, Inc. acquisition and higher jet fuel demand as restrictions from the pandemic continue to ease.

06:16 EDT Chevron reports Q3 cash flow from operations $15.3B, free cash flow $12.3B

06:04 EDT Fortis announces 2023-2027 capital plan of C$22.3B - Fortis' C$4B annual capital plan remains on track with C$2.9B invested through September. The Corporation announced its new 2023-2027 capital plan of C$22.3B, the largest in the corporation's history, and C2.3B higher than the previous five-year plan. The increase is driven by organic growth, largely reflecting regional transmission projects associated with the Midcontinent Independent System Operator long-range transmission plan at ITC, additional cleaner energy investments in Arizona to support Tucson Electric Power's exit from coal by 2032, and enhancements to distribution reliability and capacity, as well as investments to support customer growth, across the corporation's regulated utilities. Approximately C$500M of the increase is driven by a higher assumed U.S.-to-Canadian dollar exchange rate over the five-year period.